Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 31;56(1):6-16.
doi: 10.5045/br.2021.2020083.

Updated recommendations for the treatment of venous thromboembolism

Affiliations
Review

Updated recommendations for the treatment of venous thromboembolism

Junshik Hong et al. Blood Res. .

Abstract

Venous thromboembolism (VTE), which includes pulmonary embolism and deep vein thrombosis, is a condition characterized by abnormal blood clot formation in the pulmonary arteries and the deep venous vasculature. It is often serious and sometimes even fatal if not promptly and appropriately treated. Moreover, the later consequences of VTE may result in reduced quality of life. The treatment of VTE depends on various factors, including the type, cause, and patient comorbidities. Furthermore, bleeding may occur as a side effect of VTE treatment. Thus, it is necessary to carefully weigh the benefits versus the risks of VTE treatment and to actively monitor patients undergoing treatment. Asian populations are known to have lower VTE incidences than Western populations, but recent studies have shown an increase in the incidence of VTE in Asia. A variety of treatment options are currently available owing to the introduction of direct oral anticoagulants. The current VTE treatment recommendation is based on evidence from previous studies, but it should be applied with careful consideration of the racial, genetic, and social characteristics in the Korean population.

Keywords: Anticoagulants; Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism.

PubMed Disclaimer

Conflict of interest statement

Authors’ Disclosures of Potential Conflicts of Interest

No potential conflicts of interest relevant to this article were reported.

Figures

Fig. 1
Fig. 1
Overview of anticoagulant therapy for venous thromboembolism. a)Doses can be modified according to organ function, body weight, or concomitant medications. Abbreviations: INR, international normalized ratio; LMWH, low-molecular-weight heparin; UFH, unfractionated heparin. Abbreviations: INR, international normalized ratio; LMWH, low-molecular-weight heparin; UFH, unfractionated heparin.
Fig. 2
Fig. 2
Pregnancy-adapted YEARS algorithm for suspected acute pulmonary embolism in pregnant patients. a)If a woman has clinical sign of DVT, check compression ultrasonography of the symptomatic leg and initiate anticoagulant if DVT is confirmed. b)Initiate ant-icoagulant if chest CTPA indicates PE. Abbreviations: CTPA, computed pulmonary angiography; DVT, deep vein thrombosis; PE, pulmonary embolism.

References

    1. Lee CH, Lin LJ, Cheng CL, Kao Yang YH, Chen JY, Tsai LM. Incidence and cumulative recurrence rates of venous thrombo-embolism in the Taiwanese population. J Thromb Haemost. 2010;8:1515–23. doi: 10.1111/j.1538-7836.2010.03873.x. - DOI - PubMed
    1. Jang MJ, Bang SM, Oh D. Incidence of venous thromboembolism in Korea: from the Health Insurance Review and Assessment Service database. J Thromb Haemost. 2011;9:85–91. doi: 10.1111/j.1538-7836.2010.04108.x. - DOI - PubMed
    1. Hong J, Lee JH, Yhim HY, et al. Incidence of venous thrombo-embolism in Korea from 2009 to 2013. PLoS One. 2018;13:e0191897. doi: 10.1371/journal.pone.0191897. - DOI - PMC - PubMed
    1. Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet. 2012;379:1835–46. doi: 10.1016/S0140-6736(11)61904-1. - DOI - PubMed
    1. White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107(23 Suppl 1):I4–8. doi: 10.1161/01.CIR.0000078468.11849.66. - DOI - PubMed